Ascendis Pharma AS (ASND) — Cash Flow-to-Debt Ratio
Ascendis Pharma AS (ASND) has a Cash Flow-to-Debt Ratio of -0.01x as of March 2026, meaning its operating cash flow of $-7.85 Million could theoretically repay 0% of its total liabilities ($1.52 Billion) in one year. See Ascendis Pharma AS free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ascendis Pharma AS Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Ascendis Pharma AS across 14 annual periods. For the full cash flow conversion analysis, see Ascendis Pharma AS (ASND) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Ascendis Pharma AS (2012–2025)
Year-by-year debt coverage analysis for Ascendis Pharma AS. Check Ascendis Pharma AS earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | $51.77 Million | $1.46 Billion | ▲ +114.8% |
| 2024 | -0.24x | $-306.20 Million | $1.29 Billion | ▲ +50.5% |
| 2023 | -0.48x | $-467.36 Million | $971.28 Million | ▲ +19.8% |
| 2022 | -0.60x | $-495.70 Million | $826.39 Million | ▲ +71.1% |
| 2021 | -2.07x | $-417.65 Million | $201.29 Million | ▼ -7.8% |
| 2020 | -1.92x | $-271.55 Million | $141.08 Million | ▲ +12.9% |
| 2019 | -2.21x | $-175.94 Million | $79.62 Million | ▲ +38.0% |
| 2018 | -3.57x | $-138.80 Million | $38.92 Million | ▲ +10.9% |
| 2017 | -4.00x | $-95.10 Million | $23.77 Million | ▲ +10.5% |
| 2016 | -4.47x | $-60.18 Million | $13.46 Million | ▼ -17.7% |
| 2015 | -3.80x | $-43.47 Million | $11.45 Million | ▼ -165.4% |
| 2014 | -1.43x | $-18.40 Million | $12.86 Million | ▼ -562.6% |
| 2013 | 0.31x | $6.31 Million | $20.40 Million | ▲ +1231.5% |
| 2012 | -0.03x | $-652.00K | $23.85 Million | — |